Search

Author/Creator Drescher, Edit

1. AB0416 A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. (June 2019)

Authors:
Yamanaka, Hisashi; Kamatani, Naoyuki; Tanaka, Yoshiya; Hibino, Toshihiko; Drescher, Edit; Sánchez-Bursón, Juan; Rettenbacher, Manfred; Bhatia, Girish; Gadve, Snehal; Shah, Chirag; Bakhle, Dhananjay
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78(2019)Supplement 2
Page Start:
1670
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Issue 1 (29th September 2016)

Authors:
Dougados, Maxime; van der Heijde, Désirée; Chen, Ying-Chou; Greenwald, Maria; Drescher, Edit; Liu, Jiajun; Beattie, Scott; Witt, Sarah; de la Torre, Inmaculada; Gaich, Carol; Rooney, Terence; Schlichting, Douglas; de Bono, Stephanie; Emery, Paul
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 1(2017)
Page Start:
88
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Issue 3 (15th May 2012)

Authors:
Tak, Paul P; Balanescu, Andra; Tseluyko, Vira; Bojin, Silvia; Drescher, Edit; Dairaghi, Dan; Miao, Shichang; Marchesin, Vittorio; Jaen, Juan; Schall, Thomas J; Bekker, Pirow
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Issue 3(2013)
Page Start:
337
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Issue 1 (8th May 2018)

Authors:
van der Heijde, Desirée; Dougados, Maxime; Chen, Ying-Chou; Greenwald, Maria; Drescher, Edit; Klar, Rena; Xie, Li; de la Torre, Inmaculada; Rooney, Terence P; Witt, Sarah L; Schlichting, Douglas E; de Bono, Stephanie; Emery, Paul
Journal:
RMD open
Issue:
Volume 4:Issue 1(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Issue 2 (27th November 2014)

Authors:
Keystone, Edward C; Taylor, Peter C; Drescher, Edit; Schlichting, Douglas E; Beattie, Scott D; Berclaz, Pierre-Yves; Lee, Chin H; Fidelus-Gort, Rosanne K; Luchi, Monica E; Rooney, Terence P; Macias, William L; Genovese, Mark C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74:Issue 2(2015)
Page Start:
333
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. (June 2022)

Authors:
Fleischmann, Roy; Friedman, Alan; Drescher, Edit; Singhal, Atul; Cortes-Maisonet, Gregorio; Doan, Thao; Lu, Wenjing; Wang, Zailong; Nader, Ahmed; Housley, William; Cohen, Stanley; Taylor, Peter C; Blanco, Ricardo
Journal:
Lancet
Issue:
Volume 4:Number 6(2022)
Page Start:
e395
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Issue 9 (25th August 2016)

Authors:
Mease, Philip J.; Gottlieb, Alice B.; Berman, Alberto; Drescher, Edit; Xing, Jun; Wong, Robert; Banerjee, Subhashis
Journal:
Arthritis & rheumatology
Issue:
Volume 68:Issue 9(2016)
Page Start:
2163
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Issue 9 (September 2016)

Authors:
Mease, Philip J.; Gottlieb, Alice B.; Berman, Alberto; Drescher, Edit; Xing, Jun; Wong, Robert; Banerjee, Subhashis
Journal:
Arthritis & rheumatology
Issue:
Volume 68:Issue 9(2016)
Page Start:
2163
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study. Issue 10 (23rd September 2015)

Authors:
Weinblatt, Michael E.; Mease, Philip; Mysler, Eduardo; Takeuchi, Tsutomu; Drescher, Edit; Berman, Alberto; Xing, Jun; Zilberstein, Moshe; Banerjee, Subhashis; Emery, Paul
Journal:
Arthritis & rheumatology
Issue:
Volume 67:Issue 10(2015)
Page Start:
2591
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Issue 8 (27th January 2017)

Authors:
van der Heijde, Désirée; Deodhar, Atul; Wei, James C; Drescher, Edit; Fleishaker, Dona; Hendrikx, Thijs; Li, David; Menon, Sujatha; Kanik, Keith S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 8(2017)
Page Start:
1340
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗